Section Arrow
Quote
CMMB.NASDAQ
- Chemomab Therapeutics Ltd
Quotes are at least 15-min delayed:2026/01/02 06:46 EST
Pre Market
Last
 --
-- (--)
Bid
1.59
Ask
1.92
High -- 
Low -- 
Volume -- 
Regular Hours (Closed)
Last
 1.65
+0.01 (+0.61%)
Day High 
1.73 
Prev. Close
1.64 
1-M High
2.77 
Volume 
110.55K 
Bid
1.59
Ask
1.92
Day Low
1.6 
Open
1.64 
1-M Low
1.5987 
Market Cap 
10.09M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 1.88 
20-SMA 2.16 
50-SMA 2.54 
52-W High 9.84 
52-W Low 0.8288 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.44/-1.06
Enterprise Value
10.30M
Balance Sheet
Book Value Per Share
1.82
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
MREOMereo BioPharma Group plc0.4167+0.0462+12.47%-- 
Pre Market 0.4438 +0.0271 +6.50%
OTLKOutlook Therapeutics1.58-0.285-15.28%0.58PE
Pre Market 0.6011 -0.9789 -61.96%
VNDAVanda Pharmaceuticals8.82+1.79+25.46%126.25PE
Pre Market 8.79 -0.03 -0.34%
SLSSELLAS Life Sciences Group3.77+0.46+13.90%-- 
Pre Market 4.44 +0.67 +17.77%
FBLGFibroBiologics0.2249-0.017-7.03%-- 
Pre Market 0.23 +0.0051 +2.27%
Industry overview quotes are at least 15 minutes delayed
Business Description
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.